<DOC>
	<DOCNO>NCT00745797</DOCNO>
	<brief_summary>1 . Patients confirm advanced NSCLC response 3-6 cycle chemotherapy , randomize receive PCI ( 30 Gy/10fr ) PCI . 2 . The primary endpoint cumulative incidence symptomatic brain metastasis ( BM ) . 3 . The study size detect hazard ratio 0.37 80 % power 2-sided 5 % significance ( 60 event , 206 patient ) .</brief_summary>
	<brief_title>Prophylactic Cranial Irradiation ( PCI ) Versus PCI Non Small Cell Lung Cancer After Response Chemotherapy</brief_title>
	<detailed_description>1 . Prophylactic cranial irradiation ( PCI ) significantly reduce risk brain metastasis ( BM ) improve survival patient extensive disease small cell lung cancer response chemotherapy . 2 . PCI also demonstrate reduce delay incidence CNS failure non small cell lung cancer patient primary therapy . 3 . But impact overall disease free survival uncertain .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>1 . Patients require histologically cytologically document NSCLC brain metastasis document magnetic resonance imaging ( MRI ) within 21 day confirm response ( RR+SD ) chemotherapy 2 . No previous history radiotherapy surgery brain 3 . Agree radiotherapy 4. age &gt; 18 &lt; 75 year 5 . ECOG performance status 1 less 6 . Good renal hepatic haematological ( absolute neutrophil count 15 x1O9/L platelet count 90 x 109/L , HB &gt; =80g /DL ) function 7 . Have provide informed consent 1 . Seizure control drug 2 . Combined disease brain tumour infarction 3 . Hypersensitivity MR enhancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>nonsmall cell lung cancer</keyword>
	<keyword>brain metastasis</keyword>
	<keyword>prophylactic cranial irradiation</keyword>
</DOC>